GlaxoSmithKline reports promising phase III trial results for new ovarian cancer treatment.

GlaxoSmithKline reported positive results from a phase III trial combining Zejula and Jemperli for first-line advanced ovarian cancer. The treatment showed a statistically significant improvement in progression-free survival compared to standard chemotherapy, though overall survival did not meet statistical significance. The company will continue to evaluate and share full results with health authorities.

3 months ago
8 Articles